Elixinol Global Stock Price To Earning
| ELLXF Stock | USD 0.01 0.01 248.78% |
Fundamental analysis of Elixinol Global allows traders to better anticipate movements in Elixinol Global's stock price by examining its financial health and performance throughout various phases of its business cycle.
Elixinol |
Elixinol Global Company Price To Earning Analysis
Elixinol Global's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Elixinol Global has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The price to earning for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Price Exposure Probability Now
Price Exposure ProbabilityAnalyze equity upside and downside potential for a given time horizon across multiple markets |
| All Next | Launch Module |
Elixinol Fundamentals
| Return On Equity | -0.71 | |||
| Return On Asset | -0.33 | |||
| Profit Margin | (1.72) % | |||
| Operating Margin | (1.63) % | |||
| Current Valuation | 2.06 M | |||
| Shares Outstanding | 316.27 M | |||
| Shares Owned By Insiders | 15.67 % | |||
| Shares Owned By Institutions | 4.83 % | |||
| Price To Book | 0.72 X | |||
| Price To Sales | 0.59 X | |||
| Revenue | 14.13 M | |||
| Gross Profit | 4.9 M | |||
| EBITDA | (24.15 M) | |||
| Net Income | (17.02 M) | |||
| Cash And Equivalents | 6.93 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 250 K | |||
| Debt To Equity | 0.17 % | |||
| Current Ratio | 3.58 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (14.07 M) | |||
| Earnings Per Share | (0.04) X | |||
| Number Of Employees | 17 | |||
| Beta | 1.71 | |||
| Market Capitalization | 6.5 M | |||
| Total Asset | 25.33 M | |||
| Z Score | 15.0 | |||
| Net Asset | 25.33 M |
About Elixinol Global Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elixinol Global's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elixinol Global using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elixinol Global based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Other Information on Investing in Elixinol Pink Sheet
Elixinol Global financial ratios help investors to determine whether Elixinol Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Elixinol with respect to the benefits of owning Elixinol Global security.